Leptin and resistin levels in serum of patients with hematologic malignancies: Correlation with clinical characteristics

Basit Öğe Kaydı
dc.authorscopusid35546856700
dc.authorscopusid7004457653
dc.authorscopusid23469279400
dc.authorscopusid23062507800
dc.authorscopusid6701664192
dc.authorscopusid7003486028
dc.contributor.authorPamuk G.E.
dc.contributor.authorDemir M.
dc.contributor.authorHarmandar F.
dc.contributor.authorYeşil Y.
dc.contributor.authorTurgut B.
dc.contributor.authorVural Ö.
dc.date.accessioned2024-06-12T10:29:13Z
dc.date.available2024-06-12T10:29:13Z
dc.date.issued2006
dc.description.abstractAim: To evaluate leptin and resistin levels in patients with various hematologic malignancies. Methods: We included 21 patients with lymphoma, 14 with multiple myeloma (MM), 14 with acute leukemia, 13 with chronic lymphocytic leukemia (CLL), and 25 healthy control subjects into our study. The subjects' body mass indexes (BMI) were calculated; hematological and acute phase response parameters, serum lipid were determined; serum leptin and resistin levels were determined by ELISA. Results: Serum leptin level was significantly increased in CLL and MM groups when compared to the control group (p < 0.01). Resistin level was significantly higher in lymphoma patients than in CLL, acute leukemia and control groups (p < 0.01). In the control group, leptin level was negatively correlated with hemoglobin level (r = -0.44, p = 0.047); and in all patients with hematologic malignancies, leptin level was correlated with BMI (r = 0.32, p = 0.02). Leptin in lymphoma subjects correlated with hemoglobin level (r = 0.64, p = 0.005), resistin level correlated with the platelet count in patients with hematologic malignancies (r = 0.26, p = 0.044). In addition, leptin level had negative correlations with international prognostic score (IPS) in Hodgkin lymphoma (r = -0.9, p = 0.002) and with international prognostic index (IPI) in non-Hodgkin lymphoma (r = -0.77, p = 0.03). In CLL patients, leptin level had a correlation with the poor prognostic marker - CD38 level (r = 0.68, p = 0.03). Conclusion: We found higher leptin levels in MM and CLL patients, and higher resistin levels in lymphoma patients: this fact demonstrates that changes in adipose tissue and metabolism occur in these disease states. Copyright © Experimental Oncology, 2006.en_US
dc.identifier.endpage244en_US
dc.identifier.issn1812-9269
dc.identifier.issue3en_US
dc.identifier.pmid17080020en_US
dc.identifier.scopus2-s2.0-33750964853en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage241en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17652
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofExperimental Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Lymphocytic Leukemia; Leptin; Lymphoma; Multiple Myeloma; Resistinen_US
dc.subjectCd38 Antigen; Hemoglobin; Leptin; Resistin; Acute Leukemia; Adult; Aged; Article; Body Mass; Chronic Lymphatic Leukemia; Controlled Study; Enzyme Linked Immunosorbent Assay; Female; Hematologic Malignancy; Hemoglobin Blood Level; Hodgkin Disease; Human; Human Tissue; Lipid Blood Level; Lymphoma; Major Clinical Study; Male; Multiple Myeloma; Nonhodgkin Lymphoma; Prognosis; Protein Blood Level; Scoring System; Thrombocyte Count; Adipose Tissue; Adult; Aged; Female; Hematologic Neoplasms; Humans; Leptin; Lipid Metabolism; Male; Middle Aged; Resistinen_US
dc.titleLeptin and resistin levels in serum of patients with hematologic malignancies: Correlation with clinical characteristicsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu